Biotech Archives - Page 62 of 795

2 minute read

Brexit Impact On Drugs – Rising Shortages in UK Highlight Brexit Challenges

April 19, 11:39 AM

Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory hurdles, and global disruptions.

AZN

2 minute read

Johnson & Johnson Children’s Cough Syrup Contaminated In Some Batches – WHO Poised to Issue Global Alert

By Vandana Singh

April 19, 10:17 AM

WHO alerts the global community about tainted children's cough syrup by Johnson & Johnson. Elevated toxin levels detected in Benylin syrup prompt recalls across Africa. Investigation is underway.

JNJ

4 minute read

Studies Led By Harvard Pilgrim Health Care Institute, HCA Healthcare And The University Of California, Irvine Announce Two Clinical Trials Identified A Better Way To Target Appropriate Antibiotics For Patients Hospitalized With Pneumonia Or Urinary Tra…

By Benzinga Newsdesk

April 19, 9:31 AM

Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistanceTwo large multi-state studies uncovered a highly

HCA

1 minute read

FDA Mandates “Boxed Warning” For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

By Vandana Singh

April 19, 9:28 AM

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

BMY

1 minute read

NKGen Biotech Announces Upcoming Presentation On SNK01 NK Cell Therapy In Neurodegenerative Disease At The 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

By Benzinga Newsdesk

April 18, 4:22 PM

NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK")

NKGN

2 minute read

German Authority Gives Go Ahead To Novo Nordisk’s Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline

By Vandana Singh

April 18, 1:55 PM

Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic expansion. Deal expected to close Q2 2024.

NVO

2 minute read

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson’s Disease Study

By Vandana Singh

April 18, 1:44 PM

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.

ABBV

1 minute read

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

By Vandana Singh

April 18, 1:37 PM

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data for Paxtrava also disclosed, showing substantial reduction in intraocular pressure.

OCUL

2 minute read

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

By Vandana Singh

April 18, 1:04 PM

Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces interim findings and $40 million PIPE financing.

BNTC

3 minute read

96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

By Piero Cingari

April 18, 1:01 PM

480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth buying. Top 5 stocks with biggest gap between price and target: CCL, BIO, WBD, CZR, CCO.

BIO